

HR 465

Prescription Drug Price Relief Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 10, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jan 25, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/465>

Sponsor

Name: Rep. Khanna, Ro [D-CA-17]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (22 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Jan 10, 2019
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Jan 10, 2019
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Jan 10, 2019
Rep. Gabbard, Tulsi [D-HI-2]	D · HI		Jan 10, 2019
Rep. Jayapal, Pramila [D-WA-7]	D · WA		Jan 10, 2019
Rep. Lee, Barbara [D-CA-13]	D · CA		Jan 10, 2019
Rep. Neguse, Joe [D-CO-2]	D · CO		Jan 10, 2019
Rep. Ocasio-Cortez, Alexandria [D-NY-14]	D · NY		Jan 10, 2019
Rep. Omar, Ilhan [D-MN-5]	D · MN		Jan 10, 2019
Rep. Pocan, Mark [D-WI-2]	D · WI		Jan 10, 2019
Rep. Pressley, Ayanna [D-MA-7]	D · MA		Jan 10, 2019
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Jan 10, 2019
Rep. Tlaib, Rashida [D-MI-13]	D · MI		Jan 10, 2019
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jan 10, 2019
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jan 15, 2019
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Jan 15, 2019
Rep. Haaland, Debra A. [D-NM-1]	D · NM		Jan 15, 2019
Rep. Mucarsel-Powell, Debbie [D-FL-26]	D · FL		Jan 15, 2019
Rep. Davis, Danny K. [D-IL-7]	D · IL		Jan 22, 2019
Rep. Raskin, Jamie [D-MD-8]	D · MD		Jan 28, 2019
Rep. Roybal-Allard, Lucille [D-CA-40]	D · CA		Feb 5, 2019
Rep. Meng, Grace [D-NY-6]	D · NY		Apr 30, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 25, 2019
Judiciary Committee	House	Referred to	Jan 10, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 102	Identical bill	Jan 10, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jan 10, 2019)

Prescription Drug Price Relief Act of 2019

This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.

Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population.

The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Actions Timeline

- **Jan 25, 2019:** Referred to the Subcommittee on Health.
- **Jan 10, 2019:** Introduced in House
- **Jan 10, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Jan 10, 2019:** Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.